Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06297525
Status:
RECRUITING
Last Update Posted:
2024-03-08
First Post:
2024-02-29
Brief Title:
Study of STP938 in Advanced Solid Tumours
Sponsor:
Step Pharma SAS
Organization:
Step Pharma SAS
Study Overview
Official Title:
An Open-Label Phase 1 Study to Evaluate Safety Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy
The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy
The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None